UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

Journal of global antimicrobial resistance., 2021-06, Vol.25, p.93-101

2021

Volltextzugriff (PDF)

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

Antimicrobial Agents and Chemotherapy, 2009-03, Vol.53 (3), p.918-925

2009

Volltextzugriff (PDF)

Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae

Journal of antibiotics, 2023-03, Vol.76 (3), p.183-189

2023

Volltextzugriff (PDF)

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Journal of global antimicrobial resistance., 2024-09, Vol.38, p.71-82

2024

Volltextzugriff (PDF)

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

Antimicrobial Agents and Chemotherapy, 2010-12, Vol.54 (12), p.5369-5371

2010

Volltextzugriff (PDF)

Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection

Antimicrobial Agents and Chemotherapy, 2013-01, Vol.57 (1), p.205-211

2013

Volltextzugriff (PDF)

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

Antimicrobial Agents and Chemotherapy, 2008-05, Vol.52 (5), p.1597-1603

2008

Volltextzugriff (PDF)

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3820-3822

2008

Volltextzugriff (PDF)

Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus

Antimicrobial Agents and Chemotherapy, 2009-02, Vol.53 (2), p.800-804

2009

Volltextzugriff (PDF)

Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply

JAMA : the journal of the American Medical Association, 2023-02, Vol.329 (8), p.685

2023

Volltextzugriff (PDF)

Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too

Antimicrobial agents and chemotherapy, 2022-04, Vol.66 (4), p.e0021322-e0021322

2022

Volltextzugriff (PDF)

Identification and Characterization of a Cyclooxygenase-like Enzyme from Entamoeba Histolytica

Proceedings of the National Academy of Sciences - PNAS, 2003-11, Vol.100 (23), p.13561-13566

2003

Volltextzugriff (PDF)

Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-10, Vol.328 (13), p.1304

2022

Volltextzugriff (PDF)

Assessment of Oritavancin Serum Protein Binding across Species

Antimicrobial Agents and Chemotherapy, 2010-08, Vol.54 (8), p.3481-3483

2010

Volltextzugriff (PDF)

Strain-specific differences in the genetic control of two closely related mycobacteria

PLoS pathogens, 2010-10, Vol.6 (10), p.e1001169-e1001169

2010

Volltextzugriff (PDF)

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Antimicrobial agents and chemotherapy, 2018-01, Vol.62 (1)

2018

Volltextzugriff (PDF)

Sigmoid Emax Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime

Antimicrobial agents and chemotherapy, 2021-07, Vol.65 (8), p.e0092621-e0092621

2021

Volltextzugriff (PDF)

Sigmoid E max Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime

Antimicrobial agents and chemotherapy, 2021-07, Vol.65 (8), p.e0092621

2021

Volltextzugriff (PDF)

P38 Re-assessment of the primary efficacy outcomes of cefepime/enmetazobactam versus piperacillin/tazobactam in adult patients with complicated urinary tract infections or acute pyelonephritis using updated EUCAST piperacillin/tazobactam susceptibility breakpoints

JAC-antimicrobial resistance, 2024-08, Vol.6 (Suppl 2)

2024

Volltextzugriff (PDF)

2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Volltextzugriff (PDF)

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Volltextzugriff (PDF)

Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC

Bioorganic & medicinal chemistry letters, 2006-02, Vol.16 (4), p.891-896

2006

Volltextzugriff (PDF)

Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State

Antimicrobial agents and chemotherapy, 2016-07, Vol.60 (7), p.4342-4345

2016

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus

Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus

Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply

Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too

Identification and Characterization of a Cyclooxygenase-like Enzyme from Entamoeba Histolytica

Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial

Assessment of Oritavancin Serum Protein Binding across Species

Strain-specific differences in the genetic control of two closely related mycobacteria

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Sigmoid Emax Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime

Sigmoid E max Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime

P38 Re-assessment of the primary efficacy outcomes of cefepime/enmetazobactam versus piperacillin/tazobactam in adult patients with complicated urinary tract infections or acute pyelonephritis using updated EUCAST piperacillin/tazobactam susceptibility breakpoints

2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021

Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae

Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC

Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State

Suchergebnisse filtern